PATANASE Drug Patent Profile

When do Patanase patents expire, and when can generic versions of Patanase launch?

Patanase is a drug marketed by Novartis and is included in one NDA.

The generic ingredient in PATANASE is olopatadine hydrochloride. There are seventeen drug master file entries for this compound. Forty-six suppliers are listed for this compound. Additional details are available on the olopatadine hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Patanase

A generic version of PATANASE was approved as olopatadine hydrochloride by APOTEX INC on October 8^th, 2014.

Summary for PATANASE

US Patents:	0
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for PATANASE

Paragraph IV (Patent) Challenges for PATANASE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
PATANASE	Nasal Spray	olopatadine hydrochloride	0.665 mg/ Spray	021861	1	2009-06-29

US Patents and Regulatory Information for PATANASE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	PATANASE	olopatadine hydrochloride	SPRAY, METERED;NASAL	021861-001	Apr 15, 2008		DISCN	Yes	No

International Patents for PATANASE

See the table below for patents covering PATANASE around the world.

Country	Patent Number	Title	Estimated Expiration
Brazil	PI0210707	Composição de solução para administração tópica no tratamento de distúrbios alérgicos ou inflamatórios do olho e do nariz e seu método de preparação
Germany	60204142
Japan	S6310784	DIBENZ(B,E)OXEPIN DERIVATIVE, ANTIALLERGIC AGENT AND ANTI-INFLAMMATORY AGENT
Japan	2012107046	OLOPATADINE FORMULATION FOR TOPICAL ADMINISTRATION
Argentina	034619	FORMULACIONES DE OLOPATADINE PARA ADMINISTRACION TOPICA
Japan	5328947

Supplementary Protection Certificates for PATANASE

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3043773	21C1057	France		PRODUCT NAME: MOMETASONE OU L'UN DE SES SELS AVEC OLOPATADINE OU L'UN DE SES SELS; NAT. REGISTRATION NO/DATE: NL52121 20211026; FIRST REGISTRATION: AT - 140638 20210426
3043773	2022C/520	Belgium		PRODUCT NAME: MOMETASONE OF EEN ZOUT HIERVAN EN OLOPATADINE OF EEN ZOUT HIERVAN; AUTHORISATION NUMBER AND DATE: BE595626 20220203
3043773	2190041-0	Sweden		PRODUCT NAME: MOMETASONE OR A SALT THEREOF AND OLOPATADINE OR A SALT THEREOF; NAT. REG. NO/DATE: MT NR 60226 20210519; FIRST REG.: AT APPROVAL NR 140638 20210426
0799044	02C0040	France		PRODUCT NAME: OLOPATADINE HYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/02/217/001 20020517
3043773	SPC/GB21/077	United Kingdom		PRODUCT NAME: MOMETASONE OR A SALT THEREOF AND OLOPATADINE OR A SALT THEREOF; REGISTERED: AT 140638 20210426; UK PL 25258/0331 - 0001 20210511
3043773	301154	Netherlands		PRODUCT NAME: MOMETASON OF EEN ZOUT DAARVAN EN OLOPATADINE OF EEN ZOUT DAARVAN; NATIONAL REGISTRATION NO/DATE: RVG 126186 20211014; FIRST REGISTRATION: AT 140638 20210426

Investment Scenario and Fundamentals Analysis for PATANASE (Azelastine HCl Nasal Spray)

Last updated: February 20, 2026

What is the current market position of PATANASE?

PATANASE, marketed by Mylan (now part of Viatris), is an intranasal antihistamine spray indicated for relieving allergic rhinitis symptoms. Its primary competitors include Fluticasone (Flonase), Azelastine ophthalmic solutions, and other antihistamines. The drug's global sales peaked at approximately $150 million in 2021, primarily driven by North America and Europe.[1] Use of PATANASE has been consistent but faces competition from newer formulations and fixed-dose combination therapies.

What are the key development and regulatory factors affecting PATANASE?

The original NDA (New Drug Application) was approved by the U.S. FDA in 2003. Subsequent regulatory updates include labeling changes based on safety data and new indications in certain regions. The drug remains on the market without major patent barriers until approximately 2025, after which generic competition is expected. Regulatory trends favor approval of combination therapies and new delivery devices, which could impact future sales.

How does patent and exclusivity status influence investment perception?

Patent protection for PATANASE expired in 2014 in the U.S., though market exclusivity persisted through regulatory protections and pediatric exclusivity until approximately 2019. Commercially, patent expiry has led to increased generics in some markets, reducing margins. Future value hinges on brand recognition, formulary positioning, and potential lock-ins through insurance contracts.

What is the pipeline outlook relevant to PATANASE?

No current pipeline assets directly target PATANASE. However, competitors have launched or are developing nasal spray antihistamines and fixed-dose allergy treatments, which could erode market share. The absence of pipeline innovation for PATANASE limits growth prospects absent reformulation or new indications.

What are the key technical and commercial risks?

Technical risks include the emergence of generics post-patent expiration, which can significantly diminish revenues. Commercial risks involve market saturation, especially in mature regions, and patent challenges. Regulatory risks stem from potential safety concerns or new guidelines for antihistamine nasal sprays.

How does pricing and reimbursement impact profitability?

Pricing varies across regions, with U.S. wholesale prices around $25–$30 per spray. Reimbursement depends heavily on insurance formulary coverage; inclusion improves sales. Market access challenges in some regions, such as regulatory hurdles or restrictive formulary policies, can constrain revenue growth.

What are the strategic considerations for investors?

Investors should consider the expiration of patent protection, emerging generic competition, and the absence of near-term pipeline assets. The core market remains stable in North America and Europe, but long-term growth prospects depend on potential reformulations, new delivery devices, or expanded indications. Small market share gains will be difficult unless the company innovates or secures favorable formulary positions.

What are the financial implications?

Sales remain stable but limited. Operating margins declined post-patent expiry due to generic competition, with gross margins estimated at 50–55%. No significant R&D expenses are forecasted for PATANASE itself; future revenues rely on brand loyalty and market penetration within existing indications.

What is the competitive landscape?

Company	Key Products	Market Share (Estimated)	Patent Status	Notable Developments
Viatris (formerly Mylan)	PATANASE	10–15% in nasal antihistamines	Patent expired in 2014	Focus on cost control and generics
GlaxoSmithKline	Flonase (Fluticasone)	~30-40% in allergic rhinitis	Patents extended until 2024	Launch of combination therapies
Bayer	Astepro (azelastine)	Emerging competitor	Patent pending/expiring	New delivery auto-injectors

What does the regulatory environment indicate?

Regulatory agencies are increasingly scrutinizing nasal antihistamines for safety, especially regarding neurotoxicity reports. The FDA has issued safety communications, which may influence label updates. Reimbursement policies are evolving to favor cost-effective therapies, impacting the profitability of brands like PATANASE.

Otherwise, what are the key takeaways for potential investors?

• Patent protection expired in 2014; generic competition pressures margins.
• Sales are stable but face erosion unless market share can be maintained via formulary access.
• No significant pipeline assets diminish long-term growth prospects.
• The market is mature; future growth depends on differentiation strategies or reformulation.
• Regulatory and reimbursement environments are evolving but remain generally supportive if safety profiles are maintained.

Key Takeaways

• PATANASE's sales depend on market share retention amid generic competition.
• Patent expiry limits revenue growth potential.
• No current pipeline offers growth avenues.
• Strategic focus should incorporate market access and potential reformulations.
• Future valuation depends on brand loyalty stability and regulatory environment.

FAQs

1. When will PATANASE face generic competition?
Patent expiration in the U.S. occurred in 2014; generics entered the market shortly thereafter.

2. What is the main barrier to growth for PATANASE?
Market saturation and loss of patent exclusivity limit revenue growth.

3. Are there ongoing developments to improve PATANASE?
No current pipeline efforts target reformulation or new indications for PATANASE.

4. How does market access impact profitability?
Favorable formulary positioning and reimbursement are critical; restrictions can significantly curtail sales.

5. What are the main competitors?
Fluticasone (or Flonase) and azelastine-based products, with a combined market share exceeding 50% in allergy nasal sprays.

References

[1] IMS Health. (2022). Pharmaceutical Market Data.

[2] U.S. Food and Drug Administration. (2003). NDA approval documents for PATANASE.

[3] MarketWatch. (2022). Nasal antihistamine market analysis.